PVLA
PVLA clinical trials: PALVELLA THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where PALVELLA THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PVLA on the catalyst calendar · PVLA registry changes
- Primary completion Aug 2027Sponsor estimatePhase 2NCT07552077A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of...Palvella Therapeutics, Inc. · AngiokeratomasRecruitingPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2025ActualPhase 2NCT06653842A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of...Palvella Therapeutics, Inc. · Cutaneous Venous MalformationsActive, not recruitingPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2026ActualPhase 3NCT06239480SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsPalvella Therapeutics, Inc. · Microcystic Lymphatic MalformationActive, not recruitingPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2022ActualPhase 2NCT05050149Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic MalformationsPalvella Therapeutics, Inc. · Microcystic Lymphatic MalformationCompletedPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2023ActualPhase 3NCT05180708A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin...Palvella Therapeutics, Inc. · Pachyonychia CongenitaCompletedPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2023ActualPhase 2NCT04893486CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs)...Palvella Therapeutics, Inc. · BCCs in Gorlin Syndrome PatientsCompletedPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2021ActualPhase 3NCT04520750VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia CongenitaPalvella Therapeutics, Inc. · Pachyonychia CongenitaCompletedPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2020ActualPhase 2/Phase 3NCT03920228Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia CongenitaPalvella Therapeutics, Inc. · Pachyonychia CongenitaCompletedPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2023Sponsor estimatePhase 3NCT05643872A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia...Palvella Therapeutics, Inc. · Pachyonychia CongenitaRecruitingPVLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner